Aspirin and cancer prevention

BMJ (Online)

Volumn 344, Issue 7851, 2012, Pages

  Kurth, Tobias ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BLEEDING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CLINICAL DECISION MAKING; COLORECTAL CANCER; DRUG EFFICACY; EDITORIAL; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859555758     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e2480     Document Type: Editorial

References (12)

1. Sneader W. The discovery of aspirin: a reappraisal. BMJ 2000;321:1591.
2. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
3. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 2012;5:164-78.
4. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009;373:1301-9.
5. Rothwell PM, Price FP, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; published online 20 March.
6. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; published online 20 March.
7. Chan AT, Cook NR. Are we ready to recommend aspirin for cancer prevention? Lancet 2012; published online 20 March.
8. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60. (Pubitemid 30660034)
9. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998;128:713-20. (Pubitemid 28204862)
10. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55. (Pubitemid 41002838)
11. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
12. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396-404.